Who is sponsoring NCT04933526?

NCT04933526 is sponsored by Shenzhen Second People's Hospital.

What drugs are being tested in NCT04933526?

Interventions in NCT04933526: Flumatinib, Dasatinib.

What condition does NCT04933526 study?

NCT04933526 studies Chronic Myeloid Leukemia in Chronic Phase.

Is NCT04933526 still recruiting?

NCT04933526 is currently status unknown. Last updated 27 July 2022.

Last reviewed 2022-07-27 · How we verify

NCT04933526

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Status unknown Phase 4 Last updated 27 July 2022

What this trial tests

Phase 4 trial testing Flumatinib in Chronic Myeloid Leukemia in Chronic Phase in 118 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
30 April 2023

30 June 2023

Quick facts

Lead sponsor	Shenzhen Second People's Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	118
Start date	1 July 2021
Primary completion	30 April 2023
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Flumatinib — full drug profile →
Dasatinib (dasatinib) — full drug profile →

Conditions studied

Chronic Myeloid Leukemia in Chronic Phase — all drugs for Chronic Myeloid Leukemia in Chronic Phase →

Sponsor

Shenzhen Second People's Hospital

Who can join

18 and older, any sex, with Chronic Myeloid Leukemia in Chronic Phase. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of switching to flumatinib versus dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase (CML-CP) in China. This is a post-marketing, interventional, double-arm, prospective, open-label, randomized controlled study in CML-CP patients in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given flumatinib or dasatinib under the conditions of informed consent and frequent monitoring according to the clinical guideline.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R, Gonçalves AC, Rutella S, Almeida AM, et al · · 2021 · cited 112× · PMID 34638304 · DOI 10.3390/cancers13194820
Novel targeted therapies in chronic myeloid leukemia.
Ashaq MS, Zhou Q, Li Z, Zhao B. · · 2024 · cited 2× · PMID 41550150 · DOI 10.1016/j.pscia.2024.100052
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.
Irgit A, Kamıs R, Sever B, Tuyun AF, et al · · 2025 · cited 2× · PMID 40346758 · DOI 10.1002/ardp.70005

Verify or expand the search:

Other trials of Flumatinib

Trials testing the same drug.

NCT05433532 — Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients · Phase 2 · completed
NCT05367765 — A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Mye · Phase 4 · not yet recruiting
NCT05071482 — Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL · Phase 4 · terminated
NCT04677439 — Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure · Phase 4 · unknown
NCT04375683 — Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL · Phase 3 · unknown

Other recruiting trials for Chronic Myeloid Leukemia in Chronic Phase

Currently open trials in the same condition.

NCT07375355 — Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China · recruiting

Other Shenzhen Second People's Hospital trials

Trials by the same sponsor.

NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting
NCT05540808 — The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis · unknown
NCT05603975 — Analgesic Effect of Esketamine in DCSB in Adultscontrolled Study · NA · unknown
NCT05465980 — Development and Validation of the Prediction Model for Cognitive Impairment · unknown
NCT05452759 — Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04933526 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Second People's Hospital
Last refreshed: 27 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04933526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing